| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 150, Issue 11 4719-4732, Copyright © 1993 by American Association of Immunologists
ARTICLES |
P Engel, Y Nojima, D Rothstein, LJ Zhou, GL Wilson, JH Kehrl and TF Tedder
Division of Tumor Immunology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115-6084.
CD22 is a B lineage-restricted member of the Ig superfamily that serves as an adhesion receptor expressed by mature B lymphocytes. In this study, the ability of different cell types to attach to COS cells transiently transfected with a full-length CD22 cDNA (COS-CD22) was examined to determine the cellular distribution of the ligand for CD22. T and B lymphocytes, monocytes, erythrocytes, and neutrophils formed specific rosettes with COS-CD22 cells at 4 degrees C. A panel of 33 new mAb directed against CD22 were developed to examine the regions of CD22 that mediate adhesion. Four of these mAb, HB22-7, -22, -23, and -33 (at 1 to 5 micrograms/ml) specifically blocked adhesion (75 to 95%) of all cell types to COS-CD22 cells. Each of these mAb cross-blocked each other's binding, suggesting that ligand binding occurs through a single region of CD22. These mAb also identify a region of CD22 distinct from those defined by previously described CD22 mAb. CD22-mediated adhesion of cell lines to COS-CD22 cells was independent of CD45RO and CDw75 expression, and it was not inhibited by mAb against known integrins. Although alpha-2,6-linked sialic acid expressed on the surface of COS cells did not serve as a ligand for CD22, the CD22 ligand may contain a critical sialic acid determinant, as neuraminidase treatment of all target cells eliminated CD22-mediated adhesion. CD22-mediated adhesion was Ca2+/Mg2+ independent, again suggesting that integrins were not involved. An inhibitory substance for CD22-mediated adhesion was found to be present in FCS and some ascites fluid. Analysis of CD22 mRNA and protein revealed that although multiple mRNA splice variants of CD22 mRNA can be detected, only a single protein isoform was detected on the cell surface. Therefore, although the identity of the CD22 ligands remains incompletely characterized, it is possible that a single major ligand is expressed by RBC and leukocytes, which binds to a single region of CD22.
This article has been cited by other articles:
|
|
 |
|
  L. Santos, K. E. Draves, M. Boton, P. K. Grewal, J. D. Marth, and E. A. Clark Dendritic Cell-Dependent Inhibition of B Cell Proliferation Requires CD22 J. Immunol., April 1, 2008; 180(7): 4561 - 4569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xiu, C. P. Wong, J.-D. Bouaziz, Y. Hamaguchi, Y. Wang, S. M. Pop, R. M. Tisch, and T. F. Tedder B Lymphocyte Depletion by CD20 Monoclonal Antibody Prevents Diabetes in Nonobese Diabetic Mice despite Isotype-Specific Differences in Fc{gamma}R Effector Functions J. Immunol., March 1, 2008; 180(5): 2863 - 2875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ramos-Casals and P. Brito-Zeron Emerging biological therapies in primary Sjogren's syndrome Rheumatology, September 1, 2007; 46(9): 1389 - 1396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Collins, O. Blixt, S. Han, B. Duong, H. Li, J. K. Nathan, N. Bovin, and J. C. Paulson High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells. J. Immunol., September 1, 2006; 177(5): 2994 - 3003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Haas, S. Sen, I. G. Sanford, A. S. Miller, J. C. Poe, and T. F. Tedder CD22 Ligand Binding Regulates Normal and Malignant B Lymphocyte Survival In Vivo. J. Immunol., September 1, 2006; 177(5): 3063 - 3073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghosh, C. Bandulet, and L. Nitschke Regulation of B cell development and B cell signalling by CD22 and its ligands {alpha}2,6-linked sialic acids Int. Immunol., April 1, 2006; 18(4): 603 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Varki and T. Angata Siglecs--the major subfamily of I-type lectins Glycobiology, January 1, 2006; 16(1): 1R - 27R. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Nitschke, F. Lajaunias, T. Moll, L. Ho, E. Martinez-Soria, S. Kikuchi, M.-L. Santiago-Raber, C. Dix, R. M. E. Parkhouse, and S. Izui Expression of aberrant forms of CD22 on B lymphocytes in Cd22a lupus-prone mice affects ligand binding Int. Immunol., January 1, 2006; 18(1): 59 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Wong Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities Clin. Cancer Res., October 1, 2005; 11(19): 7151s - 7157s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Leonard, M. Coleman, J. Ketas, M. Ashe, J. M. Fiore, R. R. Furman, R. Niesvizky, T. Shore, A. Chadburn, H. Horne, et al. Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma J. Clin. Oncol., August 1, 2005; 23(22): 5044 - 5051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Blixt, S. Head, T. Mondala, C. Scanlan, M. E. Huflejt, R. Alvarez, M. C. Bryan, F. Fazio, D. Calarese, J. Stevens, et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins PNAS, December 7, 2004; 101(49): 17033 - 17038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang and A. Varki Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis Glycobiology, November 1, 2004; 14(11): 939 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, R. Furman, M. W. Schuster, E. J. Feldman, M. Ashe, S. J. Schuster, W. A. Wegener, et al. Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma: Phase I/II Clinical Trial Results Clin. Cancer Res., August 15, 2004; 10(16): 5327 - 5334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Collins, O. Blixt, A. R. DeSieno, N. Bovin, J. D. Marth, and J. C. Paulson Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact PNAS, April 20, 2004; 101(16): 6104 - 6109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Otero and R. C. Rickert CD19 Function in Early and Late B Cell Development. II. CD19 Facilitates the Pro-B/Pre-B Transition J. Immunol., December 1, 2003; 171(11): 5921 - 5930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-P. Danzer, B. E. Collins, O. Blixt, J. C. Paulson, and L. Nitschke Transitional and marginal zone B cells have a high proportion of unmasked CD22: implications for BCR signaling Int. Immunol., October 1, 2003; 15(10): 1137 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Carnahan, P. Wang, R. Kendall, C. Chen, S. Hu, T. Boone, T. Juan, J. Talvenheimo, S. Montestruque, J. Sun, et al. Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22: Characterization of in Vitro Properties Clin. Cancer Res., September 1, 2003; 9(10): 3982S - 3990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, S. Ely, R. R. Furman, W. A. Wegener, H. J. Hansen, H. Ziccardi, M. Eschenberg, et al. Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin's Lymphoma J. Clin. Oncol., August 15, 2003; 21(16): 3051 - 3059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Quesenberry, H. Ahmed, M. T. Elola, N. O'Leary, and G. R. Vasta Diverse Lectin Repertoires in Tunicates Mediate Broad Recognition and Effector Innate Immune Responses Integr. Comp. Biol., April 1, 2003; 43(2): 323 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Martin, X. Romero, M. A. de la Fuente, V. Tovar, N. Zapater, E. Esplugues, P. Pizcueta, J. Bosch, and P. Engel CD84 Functions as a Homophilic Adhesion Molecule and Enhances IFN-{gamma} Secretion: Adhesion Is Mediated by Ig-Like Domain 1 J. Immunol., October 1, 2001; 167(7): 3668 - 3676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. de la Fuente, V. Tovar, N. Villamor, N. Zapater, P. Pizcueta, E. Campo, J. Bosch, and P. Engel Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9 Blood, June 1, 2001; 97(11): 3513 - 3520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Falco, R. Biassoni, C. Bottino, M. Vitale, S. Sivori, R. Augugliaro, L. Moretta, and A. Moretta Identification and Molecular Cloning of p75/AIRM1, A Novel Member of the Sialoadhesin Family That Functions as an Inhibitory Receptor in Human Natural Killer Cells J. Exp. Med., September 20, 1999; 190(6): 793 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Tuscano, A. Riva, S. N. Toscano, T. F. Tedder, and J. H. Kehrl CD22 Cross-Linking Generates B-Cell Antigen Receptor-Independent Signals That Activate the JNK/SAPK Signaling Cascade Blood, August 15, 1999; 94(4): 1382 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. GAO, R. ZHONG, J. JIANG, B. GARCIA, J. J. XING, M. J. WHITE, and A. I. LAZAROVITS Adoptively Transferable Tolerance Induced by CD45RB Monoclonal Antibody J. Am. Soc. Nephrol., February 1, 1999; 10(2): 374 - 381. [Abstract] [Full Text]
|
|
|
|
|
|
M. Konopleva, Z. Estrov, S. Zhao, M. Andreeff, and K. Mehta Ligation of Cell Surface CD38 Protein with Agonistic Monoclonal Antibody Induces a Cell Growth Signal in Myeloid Leukemia Cells J. Immunol., November 1, 1998; 161(9): 4702 - 4708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Razi and A. Varki Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes PNAS, June 23, 1998; 95(13): 7469 - 7474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Snapp, H. Ding, K. Atkins, R. Warnke, F. W. Luscinskas, and G. S. Kansas A Novel P-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Recognizes an Epitope Within the Tyrosine Sulfate Motif of Human PSGL-1 and Blocks Recognition of Both P- and L-Selectin Blood, January 1, 1998; 91(1): 154 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. de la Fuente, P. Pizcueta, M. Nadal, J. Bosch, and P. Engel CD84 Leukocyte Antigen Is a New Member of the Ig Superfamily Blood, September 15, 1997; 90(6): 2398 - 2405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nath, P. A. van der Merwe, Sør. Kelm, P. Bradfield, and P. R. Crocker The Amino-terminal Immunoglobulin-like Domain of Sialoadhesin Contains the Sialic Acid Binding Site J. Biol. Chem., November 3, 1995; 270(44): 26184 - 26191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Doody, L. Justement, C. Delibrias, R. Matthews, J Lin, M. Thomas, and D. Fearon A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP Science, July 14, 1995; 269(5221): 242 - 244. [Abstract] [PDF]
|
|
|
|
|
|
L. D. Powell and A. Varki I-type Lectins J. Biol. Chem., June 16, 1995; 270(24): 14243 - 14246. [Full Text] [PDF]
|
|
|
|
|
|
L. D. Powell, R. K. Jain, S. Sabesan, and A. Varki Characterization of Sialyloligosaccharide Binding by Recombinant Soluble and Native Cell-associated CD22 J. Biol. Chem., March 31, 1995; 270(13): 7523 - 7532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hanasaki, A. Varki, and L. D. Powell CD22-mediated Cell Adhesion to Cytokine-activated Human Endothelial Cells J. Biol. Chem., March 31, 1995; 270(13): 7533 - 7542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hanasaki and A. Varki Binding of Human Plasma Sialoglycoproteins by the B Cell-specific Lectin CD22 J. Biol. Chem., March 31, 1995; 270(13): 7543 - 7550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kelm, J. Gerlach, R. Brossmer, C.-P. Danzer, and L. Nitschke The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor Compound J. Exp. Med., May 6, 2002; 195(9): 1207 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Jin, P. A. McLean, B. G. Neel, and H. H. Wortis Sialic Acid Binding Domains of CD22 Are Required For Negative Regulation of B Cell Receptor Signaling J. Exp. Med., May 6, 2002; 195(9): 1199 - 1205. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
